Abstract:We are developing a Virtual Eye for in silico therapies to accelerate research and drug development. In this paper, we present a model for drug distribution in the vitreous body that enables personalized therapy in ophthalmology. The standard treatment for age-related macular degeneration is anti-vascular endothelial growth factor (VEGF) drugs administered by repeated injections. The treatment is risky, unpopular with patients, and some of them are unresponsive with no alternative treatment. Much attention is paid to the efficacy of these drugs, and many efforts are being made to improve them. We are designing a mathematical model and performing long-term three-dimensional Finite Element simulations for drug distribution in the human eye to gain new insights in the underlying processes using computational experiments. The underlying model consists of a time-dependent convection-diffusion equation for the drug coupled with a steady-state Darcy equation describing the flow of aqueous humor through the vitreous medium. The influence of collagen fibers in the vitreous on drug distribution is included by anisotropic diffusion and the gravity via an additional transport term. The resulting coupled model was solved in a decoupled way: first the Darcy equation with mixed finite elements, then the convection-diffusion equation with trilinear Lagrange elements. Krylov subspace methods are used to solve the resulting algebraic system. To cope with the large time steps resulting from the simulations over 30 days (operation time of 1 anti-VEGF injection), we apply the strong A-stable fractional step theta scheme. Using this strategy, we compute a good approximation to the solution that converges quadratically in both time and space. The developed simulations were used for the therapy optimization, for which specific output functionals are evaluated. We show that the effect of gravity on drug distribution is negligible, that the optimal pair of injection angles is (50∘,50∘), that larger angles can result in 38% less drug at the macula, and that in the best case only 40% of the drug reaches the macula while the rest escapes, e.g., through the retina, that by using heavier drug molecules, more of the drug concentration reaches the macula in an average of 30 days. As a refined therapy, we have found that for longer-acting drugs, the injection should be made in the center of the vitreous, and for more intensive initial treatment, the drug should be injected even closer to the macula. In this way, we can perform accurate and efficient treatment testing, calculate the optimal injection position, perform drug comparison, and quantify the effectiveness of the therapy using the developed functionals. We describe the first steps towards virtual exploration and improvement of therapy for retinal diseases such as age-related macular degeneration.

A First-Passage Model of Intravitreal Drug Delivery and Residence Time-Influence of Ocular Geometry, Individual Variability, and Injection Location

A first passage model of intravitreal drug delivery and residence time, in relation to ocular geometry, individual variability, and injection location

Models and Algorithms for the Refinement of Therapeutic Approaches for Retinal Diseases

Computational modeling of intraocular drug delivery supplied by porous implants

{Computer Modeling of Bevacizumab Drug Distribution after Intravitreal Injection in Rabbit and Human Eyes}

Computational Model of In Vivo Corneal Pharmacokinetics and Pharmacodynamics of Topically Administered Ophthalmic Drug Products

Ocular barriers to retinal delivery of intravitreal liposomes: Impact of vitreoretinal interface

A Physiology-Based Mathematical Model to Understand Drug Delivery from Contact Lenses to the Back of the Eye

Mathematical Models of Ocular Drug Delivery

Intraocular Distribution and Kinetics of Intravitreally Injected Antibodies and Nanoparticles in Rabbit Eyes

Compartmental and COMSOL Multiphysics 3D Modeling of Drug Diffusion to the Vitreous Following the Administration of a Sustained-Release Drug Delivery System

Drug Delivery from a Ring Implant Attached to Intraocular Lens: An in-silico Investigation

Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability

Mathematical Model of Macromolecular Drug Transport in a Partially Liquefied Vitreous Humor

Interfacial behavior of intravitreally injected drugs simulated by models of the silicone oil filled eye

Mathematical Models of Retinal Drug Delivery

Evaluation of protein drug stability with vitreous humor in a novel ex-vivo intraocular model

A comprehensive insight on ocular pharmacokinetics

Ocular Drug Delivery: Present Innovations and Future Challenges

Pharmacokinetic aspects of retinal drug delivery

An Intravitreal Implant Injection Method for Sustained Drug Delivery into Mouse Eyes